The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: 2.50 (5.81%)
Spread: 1.00 (2.222%)
Open: 43.10
High: 45.75
Low: 43.10
Prev. Close: 43.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta tumbles after raising £25.7m in heavily discounted placing

Thu, 29th Feb 2024 08:27

(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.

The company said it had successfully placed just under 51.3m shares at 50p each - a 34% discount to the closing share price on Tuesday - raising gross proceeds of £25.7m.

Avacta had initially been planning to raise around £20m, but the figure was increased due to "strong demand" from existing investors and potential new holders.

Announcing the placing on Wednesday, Avacta said the majority of the proceeds would be used to initiate and progress the dose expansion and Phase 2 efficacy studies for its lead pre|CISIONTM clinical programme, AVA6000, a tumour targeted form of the chemotherapy drug doxorubicin, and for general working capital until the end of 2025.

The dose expansions are expected to begin in H2 2024 in the USA, followed by the Phase 2 efficacy study, subject to funding and Food and Drug Administration approval, "which the board considers to be a major value-driving event for the group," it said.

Chief executive Alastair Smith said: "Under very challenging market conditions we have raised financing that allows Avacta to progress at full speed its lead pre|CISION targeted chemotherapy, AVA6000, into the expansion and Phase 2 efficacy studies. The emerging clinical data from the Phase 1 safety study strongly supports our belief that pre|CISION can change the way in which cancer is treated and we are pleased that we are now in a position to also progress the broader pre|CISION pipeline.

"Critically, this financing provides Avacta with 24 months of cash runway to focus on advancing AVA6000 through the clinic, as well as progressing other assets earlier in the development cycle to hit key commercial milestones."

At 0925 GMT, the shares were down 28% at 53.88p.

More News
4 Aug 2021 17:53

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

Read more
14 Jul 2021 11:30

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

Read more
14 Jul 2021 11:10

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

IN BRIEF: Avacta wins manufacturer certification for lateral flow test

Read more
14 Jul 2021 09:02

Avacta gets ISO certification for Affirmer manufacture and distribution

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced on Wednesday that its life sciences diagnostics division has achieved ISO 13485 certification on the quality management system for the manufacture and distribution of 'Affimer' reagents, for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

Read more
29 Jun 2021 12:12

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

IN BRIEF: Avacta's lateral flow test detects Covid Delta variant

Read more
29 Jun 2021 11:37

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs

Read more
29 Jun 2021 08:36

Avacta rapid Covid-19 test detects Delta variant in study

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group announced on Tuesday that a study has shown that its 'AffiDX' antigen lateral flow test detects the 'Delta' variant of the SARS-CoV-2 virus in clinical samples.

Read more
23 Jun 2021 10:28

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

Read more
21 Jun 2021 19:24

IN BRIEF: Avacta signs distribution deal for its Covid test

IN BRIEF: Avacta signs distribution deal for its Covid test

Read more
21 Jun 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
21 Jun 2021 08:37

Avacta enters non-exclusive distribution deal for Covid-19 test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has entered into a non-exclusive distribution agreement with life science products company Calibre Scientific, it announced on Monday, for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use in the UK and the European Economic Area (EEA).

Read more
11 Jun 2021 12:27

Avacta to sell rapid Covid-19 test in EU following registration

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.

Read more
11 Jun 2021 11:40

Avacta Covid lateral flow test gets regulatory green light in EU

Avacta Covid lateral flow test gets regulatory green light in EU

Read more
7 Jun 2021 11:31

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

Read more
7 Jun 2021 10:11

Avacta gets MHRA registration for rapid Covid-19 test

(Sharecast News) - Diagnostics and cancer therapy developer Avacta Group announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test for Covid-19, allowing it to place the product on the market in the UK for professional use.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.